AI startups have raised $1.5 billion in advertising funds.
The story so far
OpenEvidence, a literature-based drug discovery AI startup, may have been used by doctors. The company's economic value is expected to far exceed charges to hospitals or advertisers. Tarashansky joined the company to support clinical work. Doctors' spontaneous adoption of OpenEvidence software suggests it has a certain degree of differentiated advantage. A Mayo Clinic study found that the software provided accurate, evidence-based recommendations in all five patient case studies. However, another study, including a June paper published in Nature, found that it performed worse than general AI models like Google's Gemini and OpenAI's GPT in clinical benchmarks. NYU Langone neurosurgeon Eric Oermann said there is a lack of research on the performance of individual AI tools and guidance on implementing tools in clinical environments.
AI-written from the reports · Updated 27 days ago
Coverage timeline
Follow the coverage to see every side of the story.
- Ars Technica · AIThe $15 billion ad-powered AI startup your doctor may already be using
OpenEvidence focuses on literature-based drug discovery, with its economic value expected to far exceed charges to hospitals or advertisers. Tarashansky, the creator of Anthropic platform Claude Science, has joined the company to support clinical work.